MIOCHOL by Novartis is clinical pharmacology acetylcholine is a naturally occurring neurohormone which mediates nerve impulse transmission at all cholinergic sites involving somatic and autonomic nerves. First approved in 1973.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
MIOCHOL is a direct-acting cholinergic agonist (acetylcholine) formulated as an intraocular solution for ophthalmic use. It causes rapid miosis (pupil constriction) by mimicking acetylcholine at muscarinic receptors in the iris sphincter muscle. The drug is administered directly into the anterior chamber during eye surgery to achieve surgical miosis.
Product is in late-stage lifecycle with modest competitive pressure (30/100), indicating a consolidating team focused on retention and cost management rather than growth.
CLINICAL PHARMACOLOGY Acetylcholine is a naturally occurring neurohormone which mediates nerve impulse transmission at all cholinergic sites involving somatic and autonomic nerves. After release from the nerve ending, acetylcholine is rapidly inactivated by the enzyme acetylcholinesterase by…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MIOCHOL offers stability in a mature, niche therapeutic area rather than high-growth opportunity. Career value lies in operational excellence, healthcare channel management, and defending market position against erosion and competing techniques.
Worked on MIOCHOL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.